{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:57:57Z","timestamp":1791928677623,"version":"4.3.4"},"reference-count":39,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"7","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1167\/iovs.18-24021","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T09:33:14Z","timestamp":1527845594000},"page":"2679","source":"Crossref","is-referenced-by-count":8,"title":["CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases"],"prefix":"10.1167","volume":"59","author":[{"given":"Adrien","family":"Henry","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, H\u00f4pital Robert Debr\u00e9, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Boulagnon-Rombi","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Robert Debr\u00e9, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Menguy","sequence":"additional","affiliation":[{"name":"ElsaLys Biotech, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Giustiniani","sequence":"additional","affiliation":[{"name":"INSERM U976, H\u00f4pital Saint-Louis, UMR-S 976, Universit\u00e9 Paris Diderot, Paris, France"},{"name":"Department of Research, Institut Jean Godinot, Reims, France"},{"name":"Derm-I-C Research Unit, EA-7319, Facult\u00e9 de M\u00e9decine de Reims, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Garbar","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Robert Debr\u00e9, Reims, France"},{"name":"Department of Research, Institut Jean Godinot, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Mascaux","sequence":"additional","affiliation":[{"name":"Department of Research, Institut Jean Godinot, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Labrousse","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Facult\u00e9 de M\u00e9decine de Reims, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Milas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, H\u00f4pital Robert Debr\u00e9, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Barbe","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, H\u00f4pital Robert Debr\u00e9, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Bensussan","sequence":"additional","affiliation":[{"name":"INSERM U976, H\u00f4pital Saint-Louis, UMR-S 976, Universit\u00e9 Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Durlach","sequence":"additional","affiliation":[{"name":"Cardiovascular and Thoracic Division, H\u00f4pital Robert Debr\u00e9, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Arndt","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, H\u00f4pital Robert Debr\u00e9, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"i1552-5783-59-7-2679-b01","doi-asserted-by":"crossref","unstructured":"Fletcher EC, Chong NV. Looking beyond Lucentis on the management of macular degeneration. Eye. 2008; 22: 742\u2013750.","DOI":"10.1038\/sj.eye.6703008"},{"key":"i1552-5783-59-7-2679-b02","doi-asserted-by":"crossref","unstructured":"Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117: 1064\u20131077.","DOI":"10.1016\/j.ophtha.2010.02.031"},{"key":"i1552-5783-59-7-2679-b03","unstructured":"Dhoot DS, Avery RL. Vascular endothelial growth factor inhibitors for diabetic retinopathy. Curr Diab Rep. 2016; 122: 1\u20137."},{"key":"i1552-5783-59-7-2679-b04","doi-asserted-by":"crossref","unstructured":"Pozarowska D, Pozarowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol. 2016; 3: 311\u2013316.","DOI":"10.5114\/ceji.2016.63132"},{"key":"i1552-5783-59-7-2679-b05","doi-asserted-by":"crossref","unstructured":"Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006; 26: 1006\u20131013.","DOI":"10.1097\/01.iae.0000246884.76018.63"},{"key":"i1552-5783-59-7-2679-b06","doi-asserted-by":"crossref","unstructured":"Al-Latayfeh M, Silva PS, Sun JK, et al. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med. 2012; 26: a006411.","DOI":"10.1101\/cshperspect.a006411"},{"key":"i1552-5783-59-7-2679-b07","doi-asserted-by":"crossref","unstructured":"Klein A, Loewenstein A. therapeutic monoclonal antibodies and fragments: bevacizumab. Dev Ophthalmol. 2015; 55: 232\u2013245.","DOI":"10.1159\/000431199"},{"key":"i1552-5783-59-7-2679-b08","doi-asserted-by":"crossref","unstructured":"Duch S, Buchacra O, Milla E, et al. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009; 18: 140\u2013143.","DOI":"10.1097\/IJG.0b013e318170a747"},{"key":"i1552-5783-59-7-2679-b09","doi-asserted-by":"crossref","unstructured":"Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma. J Glaucoma. 2009; 18: 632\u2013637.","DOI":"10.1097\/IJG.0b013e3181997211"},{"key":"i1552-5783-59-7-2679-b10","doi-asserted-by":"crossref","unstructured":"Erdol H, Turk A, Akyol N, et al. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation. Retina. 2010; 30: 570\u2013577.","DOI":"10.1097\/IAE.0b013e3181bf5ff0"},{"key":"i1552-5783-59-7-2679-b11","doi-asserted-by":"crossref","unstructured":"Tonello M, Costa RA, Almeida FPP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmologica. 2008; 86: 385\u2013389.","DOI":"10.1111\/j.1600-0420.2007.01056.x"},{"key":"i1552-5783-59-7-2679-b12","doi-asserted-by":"crossref","unstructured":"Osaadon P, Fagan XJ, Lifshitz T, et al. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye. 2014; 28: 510\u2013520.","DOI":"10.1038\/eye.2014.13"},{"key":"i1552-5783-59-7-2679-b13","doi-asserted-by":"crossref","unstructured":"Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2011; 96: 1\u20132.","DOI":"10.1136\/bjophthalmol-2011-301236"},{"key":"i1552-5783-59-7-2679-b14","doi-asserted-by":"crossref","unstructured":"Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008; 49: 3115\u20133116.","DOI":"10.1167\/iovs.08-1689"},{"key":"i1552-5783-59-7-2679-b15","doi-asserted-by":"crossref","unstructured":"Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008; 115: 2199\u20132205.","DOI":"10.1016\/j.ophtha.2008.07.007"},{"key":"i1552-5783-59-7-2679-b16","unstructured":"Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Ophthalmology. 2015; 159: 2292\u20132299."},{"key":"i1552-5783-59-7-2679-b17","doi-asserted-by":"crossref","unstructured":"Grunwald JE, Pistilli M, Ying G-S, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015; 122: 809\u2013816.","DOI":"10.1016\/j.ophtha.2014.11.007"},{"key":"i1552-5783-59-7-2679-b18","doi-asserted-by":"crossref","unstructured":"Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 121: 150\u2013161.","DOI":"10.1016\/j.ophtha.2013.08.015"},{"key":"i1552-5783-59-7-2679-b19","doi-asserted-by":"crossref","unstructured":"Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382: 1258\u20131267.","DOI":"10.1016\/S0140-6736(13)61501-9"},{"key":"i1552-5783-59-7-2679-b20","doi-asserted-by":"crossref","unstructured":"Edington M, Connolly J, Chong NV. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Expert Opin Drug Metab Toxico. 2017; 13: 1217\u20131224.","DOI":"10.1080\/17425255.2017.1404987"},{"key":"i1552-5783-59-7-2679-b21","doi-asserted-by":"crossref","unstructured":"Dorrell MI, Aguilar E, Scheppke L, et al. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A. 2007; 104: 967\u2013972.","DOI":"10.1073\/pnas.0607542104"},{"key":"i1552-5783-59-7-2679-b22","doi-asserted-by":"crossref","unstructured":"Ma\u00efza H, Leca G, Mansur IG, et al. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med. 1993; 178: 1121\u20131126.","DOI":"10.1084\/jem.178.3.1121"},{"key":"i1552-5783-59-7-2679-b23","doi-asserted-by":"crossref","unstructured":"Anumathan A, Bensussan A, Boumsell L, et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol. 1998; 161: 2780\u20132790.","DOI":"10.4049\/jimmunol.161.6.2780"},{"key":"i1552-5783-59-7-2679-b24","doi-asserted-by":"crossref","unstructured":"Tsujimura K, Obata Y, Matsudaira Y, et al. Characterization of murine CD160+ CD8+ T lymphocytes. Immunol Lett. 2006; 106: 48\u201356.","DOI":"10.1016\/j.imlet.2006.04.006"},{"key":"i1552-5783-59-7-2679-b25","doi-asserted-by":"crossref","unstructured":"Ortonne N, Ram-Wolff C, Giustiniani J, et al. Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160. J Invest Dermatol. 2011; 131: 916\u2013924.","DOI":"10.1038\/jid.2010.412"},{"key":"i1552-5783-59-7-2679-b26","doi-asserted-by":"crossref","unstructured":"Barman S, Kayama H, Okuzaki D, et al. Identification of a human intestinal myeloid cell subset that regulates gut homeostasis. Int Immunol. 2016; 28: 533\u2013545.","DOI":"10.1093\/intimm\/dxw034"},{"key":"i1552-5783-59-7-2679-b27","doi-asserted-by":"crossref","unstructured":"Cai G, Anumanthan A, Brown JA, et al. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol. 2008; 9: 176\u2013185.","DOI":"10.1038\/ni1554"},{"key":"i1552-5783-59-7-2679-b28","doi-asserted-by":"crossref","unstructured":"Tu TC, Brown NK, Kim T-J, et al. CD160 is essential for NK-mediated IFN-? production. J Exp Med. 2015; 212: 415\u2013429.","DOI":"10.1084\/jem.20131601"},{"key":"i1552-5783-59-7-2679-b29","unstructured":"Liu B, Faia L, Hu M, et al. Pro-angiogenic effect of IFN? is dependent on the PI3K\/mTOR\/ translational pathway in human retinal pigmented epithelial cells. Mol Vis. 2018; 16: 184\u2013193."},{"key":"i1552-5783-59-7-2679-b30","doi-asserted-by":"crossref","unstructured":"Fons P, Chabot S, Cartwright JE, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood. 2006; 108: 2608\u20132615.","DOI":"10.1182\/blood-2005-12-019919"},{"key":"i1552-5783-59-7-2679-b31","doi-asserted-by":"crossref","unstructured":"Chabot S, Jabrane-Ferrat N, Bigot K, et al. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J Exp Med. 2011; 208: 973\u2013986.","DOI":"10.1084\/jem.20100810"},{"key":"i1552-5783-59-7-2679-b32","doi-asserted-by":"crossref","unstructured":"Ling C, Pouget C, Rech F, et al. Endothelial cell hypertrophy and microvascular proliferation in meningiomas are correlated with higher histological grade and shorter progression-free survival. J Neuropathol Exp Neurol. 2016; 75: 1160\u20131170.","DOI":"10.1093\/jnen\/nlw095"},{"key":"i1552-5783-59-7-2679-b33","doi-asserted-by":"crossref","unstructured":"Ollauri-Ib\u00e1\u00f1ez C, L\u00f3pez-Novoa JM, Pericacho M. Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies. Expert Opin Biol Ther. 2017; 17: 1053\u20131063.","DOI":"10.1080\/14712598.2017.1346607"},{"key":"i1552-5783-59-7-2679-b34","doi-asserted-by":"crossref","unstructured":"Khan KA, Bicknell R. Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metas. 2016; 33: 197\u2013210.","DOI":"10.1007\/s10585-015-9769-3"},{"key":"i1552-5783-59-7-2679-b35","doi-asserted-by":"crossref","unstructured":"Gao F, Hou H, Liang H, et al. Bone marrow-derived cells in ocular neovascularization: contribution and mechanisms. Angiogenesis. 2016 ; 19: 107\u2013118.","DOI":"10.1007\/s10456-016-9497-6"},{"key":"i1552-5783-59-7-2679-b36","unstructured":"Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002; 8: 119\u2013126."},{"key":"i1552-5783-59-7-2679-b37","doi-asserted-by":"crossref","unstructured":"Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006; 124: 175\u2013189.","DOI":"10.1016\/j.cell.2005.10.036"},{"key":"i1552-5783-59-7-2679-b38","doi-asserted-by":"crossref","unstructured":"Shen J, Xie B, Dong A, et al. In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels. Invest Ophthalmol Vis Sci. 2007; 48: 4335\u20134337.","DOI":"10.1167\/iovs.07-0113"},{"key":"i1552-5783-59-7-2679-b39","doi-asserted-by":"crossref","unstructured":"Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015; 49: 67\u201381.","DOI":"10.1016\/j.preteyeres.2015.06.002"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?articleid=2683132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:30:53Z","timestamp":1791927053000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.18-24021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.18-24021","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}